Snappy newsletters. Simple Facebook sharing. Spirited comments. Sweet features are waiting… GET THEM NOW!

Tamiflu Will Carry Stronger Warning Labels

Maker will beef up language on possible psychiatric side effects

By Jim O'Neill, Newser User

Posted Nov 28, 2007 4:51 PM CST

(Newser) – The maker of flu drug Tamiflu said today it will accept recommendations by a government panel that it revise printed warnings about the medication's side effects. Labels already warn of possible psychiatric reactions, but the panel recommended noting that some people have died, the AP... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

There are no comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Cops Shoot Naked Guy Eating Man's Face on Highway

Japanese Artist Serves Up Own Cooked Genitals

Associated Press (Source Grid »)
Bloomberg (Source Grid »)

A crisis looms
Belfast Telegraph

Orders for flu drug double
BBC

Money • Health

FDA • GlaxoSmithKline • Tamiflu • Relenza • flu medications • Roche

More Newser Stories

Swiss Pharma Won't Donate Swine Flu Vaccine to Poor

Novartis defies WHO calls to give free doses to poor

(NEWSER) - Swiss pharma giant Novartis is defying the World Health Organization by refusing to donate swine flu vaccines to the world's poor, despite the designation of H1N1 as the first pandemic in 40 years, reports the Financial Times. Last week the WHO's director general called on drug companies to show "solidarity" with low-income victims, but Novartis is telling the poor to pay up. More»

Tamiflu Useless Against Dominant Flu Strain

Substitute isn't safe for everyone

(NEWSER) - The dominant flu strain circulating in much of the US is nearly 100% resistant to Tamiflu, the most commonly used antiviral, the Los Angeles Times reports. Despite a milder than usual flu season, the resistance is still causing concern, and the CDC is advising doctors to substitute Tamiflu with Relenza, another antiviral, or mix it with an older one. More»

FDA Restricts Diabetes Drug Over Heart Risk

But regulators stop short of an outright ban on Avandia

(NEWSER) - The FDA today put severe restrictions on Avandia, GlaxoSmithKline’s embattled diabetes drug, but stopped short of banning it outright. The once-popular drug will now only be available only as a last resort to type 2 diabetes patients who can’t control their glucose levels with any other medication, the AFP reports. Avandia has come under fire because data suggests it carries, in the FDA’s words, “an elevated risk of cardiovascular events” like heart attacks and strokes. More»

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

(AP) - A majority of federal health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack. A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. The agency is not required to follow the group's advice, but it usually follows the advice of its advisory committees. More»

Avandia Woes Mount Ahead of FDA Hearing

Agency flags flawed study, may ban diabetes drug

(NEWSER) - As the FDA prepares to consider whether to ban Avandia, agency scientists have discovered another problem with the diabetes drug: flaws that disqualify a clinical study sponsored by its maker. The trial, organized by GlaxoSmithKline, sought to evaluate the relative heart risks of Avandia and two other diabetes drugs, but was an "open label" trial, meaning the researchers and patients knew which drugs they were getting, USA Today reports. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

Tamiflu Will Carry Stronger Warning Labels

Maker will beef up language on possible psychiatric side effects

FDA • GlaxoSmithKline • Tamiflu • Relenza • flu medications • Roche

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Swiss Pharma Won't Donate Swine Flu Vaccine to Poor

Novartis defies WHO calls to give free doses to poor

Tamiflu Useless Against Dominant Flu Strain

Substitute isn't safe for everyone

FDA Restricts Diabetes Drug Over Heart Risk

But regulators stop short of an outright ban on Avandia

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

Avandia Woes Mount Ahead of FDA Hearing

Agency flags flawed study, may ban diabetes drug

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?